Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles

Vaccine

Volumn 27, Issue 17, 2009, Pages 2326-2334

  Fraillery, Dominique ^a   Zosso, Nathalie ^a   Nardelli Haefliger, Denise ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Human papillomavirus virus like particles; Mucosal immunity; Rectal and vaginal immunization

Indexed keywords

BICARBONATE; CHOLERA TOXIN; ESTRADIOL; HUMAN PAPILLOMA VIRUS TYPE 16 L1 VIRUS LIKE PARTICLE VACCINE; IMIQUIMOD; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; MEDROXYPROGESTERONE ACETATE; NEUTRALIZING ANTIBODY; NONOXINOL 9; RESIQUIMOD; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BAGG ALBINO MOUSE; CONDYLOMA ACUMINATUM; DRUG ADMINISTRATION ROUTE; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, RECTAL; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CAPSID PROTEINS; CHOLERA TOXIN; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMIDAZOLES; LIPID A; MICE; MOUTH; NONOXYNOL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECTUM; VACCINES, SYNTHETIC; VAGINA;

EID: 62249122455     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.029     Document Type: Article

References (41)

1. Parkin D.M., and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24S3 (2006) S3/11-S3/25
2. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 (2002) 244-265
3. Lowy D., and Schiller J. Prophylactic human papillomavirus vaccines. J Clin Invest 116 (2006) 1167-1173
4. Nardelli-Haefliger D., Wirthner D., Schiller J., Lowy D.R., Hildesheim A., Ponci F., et al. Specific antibody levels at the cervix during the menstrual-cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 95 (2003) 1128-1137
5. Nardelli-Haefliger D., Roden R., Balmelli C., Potts A., Schiller J., and De Grandi P. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice. J Virol 74 (1999) 9609-9613
6. Nardelli-Haefliger D., Lurati F., Wirthner D., Spertini F., Schiller J.T., Lowy D.R., et al. Immune responses induced by lower airway mucosal immunization with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 23 (2005) 3634-3641
7. Gerber S., Lane C., Brown D., Lord E., DiLorenzo M., Clements J.D., et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol 75 (2001) 4752-4760
8. Mestecky J., Moldoveanu Z., and Russell M.W. Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol 53 (2005) 208-214
9. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6 (2006) 148-158
10. Balmelli C., Roden R., Potts A., Schiller J., De Grandi P., and Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 72 10 (1998) 8220-8229
11. Balmelli C., Demotz S., Acha-Orbea H., De Grandi P., and Nardelli-Haefliger D. Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles. J Virol 76 24 (2002) 12596-12602
12. Hopkins S., Kraehenbuhel J.-P., Schödel F., Potts A., Peterson D., De Grandi P., et al. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect Immun 63 (1995) 3279-3286
13. Nardelli-Haefliger D., Roden R., Benyacoub J., Sahli R., Kraehenbuhl J.P., Schiller J.T., et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun 65 8 (1997) 3328-3336
14. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321 (2004) 205-216
15. Fraillery D., Baud D., Pang S.Y., Schiller J., Bobst M., Zosso N., et al. Ty21a expressing Human papillomavirus type 16 L1 as a potential live Salmonella vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol 14 (2007) 1285-1295
16. Grewal H.M.S., Karlsen T.H., Vetvik H., Ahren C., Gjessing H.K., Sommerfelt H., et al. Measurement of specific IgA in faecal extracts and intestinal lavage fluid for monitoring of mucosal immune responses. J Immunol Methods 239 (2000) 53-62
17. Roberts J.N., Buck C.B., Thompson C.D., Kines R., Bernardo M., Choyke P.L., et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13 (2007) 857-861
18. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25 (2007) 5467-5484
19. Stanley M.A. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer. Br J Cancer 96 (2007) 1320-1323
20. Revaz V., Zurbriggen R., Moser C., Schiller J., Ponci F., Bobst M., et al. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res 76 (2007) 75-85
21. van Ginkel F.W., Jackson R.J., Yuki Y., and McGhee J.R. The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165 (2000) 4778-4782
22. Park J.S., Oh Y.K., Kang M.J., and Kim C.K. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems. J Med Virol 70 (2003) 633-641
23. Parez N., Fourgeux C., Mohamed A., Dubuquoy C., Pillot M., Dehee A., et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J Virol 80 (2006) 1752-1761
24. Tengvall S., O'ha, and Harandi A.M. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relatve importance of myeloid differentiation factor 88. Antiviral Res 78 (2008) 202-214
25. Sougioultzis S., Lee C.K., Alsahli M., Banerjee S., Cadoz M., Schrader R., et al. Safety adn efficacyof E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 21 (2002) 194-201
26. Johansson E.L., Rask C., Fredriksson M., Eriksson K., Czerkinsky C., and Holmgren J. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin b subunit or conjugates. Infect Immun 66 2 (1998) 514-520
27. Oh Y.K., Park J.-S., Yoon H., and Kim C.H. Enhanced mucosal and systemic immune responses to a vaginal vaccine coadministered with RANTES-expressing plasmid DNA using in situ-gelling mucoadhesive delivery system. Vaccine 21 (2003) 1980-1988
28. Shen X.S., Lagergard T., Yang Y., Lindblad M., Fredriksson M., and Holmgren J. Systemic and mucosal immune responses in mice after mucosal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine. Infect Immun 68 (2000) 5749-5755
29. Frey A., Giannasca K., Weltzin R., Giannasca P.J., Reggio H., Lencer W.I., et al. Role of the glycocalys in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med 184 (1996) 1045-1059
30. Iwasaki A., and Medzhitow R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 10 (2004) 987-995
31. Garland S.M. Imiquimod. Curr Opin Infect Dis 16 (2003) 85-89
32. Wu J.J., Huang D.B., and Tyring S.K. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res 64 (2004) 79-83
33. Thomsen L.L., Topley P., Daly M.G., Brett S.J., and Tite J.P. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22 (2004) 1799-1809
34. Rechtsteiner G., Warger T., Osterloh P., Schild H., and Radsak M.P. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 174 (2005) 2476-2480
35. Freytag L.C., and Clements J.D. Mucosal adjuvants. Vaccine 23 (2005) 1804-1813
36. Tomai M.A., Imbertson L.M., Stanczak T.L., Tygrett L.T., and Waldschmidt T.J. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 203 (2000) 55-65
37. Soboll G., Schaefer T.M., and Wira C.R. Effect of Toll-like receptor (TLR) agonists on TLR and microbicide expression in uterine and vaginal tissues of the mouse. Am J Reprod Immunol 55 (2006) 434-446
38. Fausch S.C., Fahey L.M., Da Silva D.M., and Kast M. Human papillomavirus can escape immune recognition through langerhans cell phosphoinositide 3-kinase activation. J Immunol 174 (2005) 7172-71-7172-78
39. Zhao X., Deak E., Soderberg K., Linehan M., Spezzano D., Zhu J., et al. Vaginal submucosal dendritic cells, but not langerhans cells, induce protective Th1 responses to Herpes simplex virus-2. J Exp Med 197 (2003) 153-162
40. Galen B.T., Martin A.P., Hazrati E., Garin A., Guzman E., Wilson S.S., et al. A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis 195 (2007) 1332-1339
41. Brandtzaeg P. Do salivary antiodies reliably reflect both mucosal and systemic immunity?. Ann N Y Acad Sci 1098 (2007) 288-311